1.	First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HOG GU10-147, NCT01215136
2.	Tesetaxel for Previously Treated Patients With Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOBL204, NCT01215877
3.	DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: N10-1, NCT01353222
4.	First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU10-148, NCT01524991
5.	Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-071, NCT01589094
6.	Phase II Trial of Neoadjuvant Dose Dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: ERP-GU-052, NCI-2012-00906, IRB#12-015, NCT01611662
7.	Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2012.038, HUM00062285, NCT01663285
8.	Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers Phase: Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-13419, NCI-2011-0098, NCT01375699
9.	Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16722, NCT01606345